Almac invests in biocatalysis lauding cost and environmental benefits

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Related tags: Active ingredient, Pharmaceutical drug

Almac invests $4m in biocatalysis R&D, describing such technologies as the way forward for the cost efficient production of highly chiral APIs and intermediates.

Outsourcing-pharma spoke with Tom Moody, head of Almac’s biocatalysis unit, who explained that the move is part of focus on bringing green manufacturing technologies to the active pharmaceutical ingredient (API) production process.

The investment, Moody continued, will increase Almac’s suite of enzyme panels, process fermentation capabilities as well as its ability to scale up these technologies for its customers.

He also predicted that Almac’s broad service portfolio of chemistry services and API manufacturing will, when combined with the expanded offering, help the firm compete in the increasingly competitive biocatalysis sector.

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

BioContinuum™ Platform - MilliporeSigma | 01-Jul-2020 | Technical / White Paper

Adoption of next generation processing and technologies can enable improvements in productivity by streamlining workflows, reducing the manufacturing plant...

Related suppliers

Follow us

Products

View more

Webinars